Health & Pharma
AstraZeneca's Weekly Myasthenia Shot Has to Beat Its Own C5 Franchise First
The FDA approved Klygefa, a once-weekly subcutaneous C5 inhibitor for generalised myasthenia gravis. Its first commercial job may be pulling patients off AstraZeneca's own C5 products while an FcRn rival grows 54%.
- Why the Liver Test Became the Real Contest in a Rare Joint Tumor
- Bayer's First-Ever Factor XIa Drug Rebuilds a Shrunken Blockbuster Bet
- CVS Is Unwinding the Deal That Built It
- J&J's Rybrevant Wins the First New Second-Line Head and Neck Cancer Drug in a Decade
- FDA Approves the First DNA-Based Immunotherapy, on a 32-Patient Trial
- A Catholic Nonprofit Is Taking Surgery Partners Private
- Hepatitis B's First Functional Cure Reaches the US Market
- AstraZeneca's Ultomiris Cuts IgAN Proteinuria 43%, but the Kidney Proof Is Still Pending
























































